{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:22:30Z","timestamp":1793694150749,"version":"4.5.1"},"reference-count":193,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.annonc.2024.04.005","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T18:06:40Z","timestamp":1716833200000},"page":"588-606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":446,"title":["Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7841-2900","authenticated-orcid":false,"given":"M.F.","family":"Mosele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5310-3754","authenticated-orcid":false,"given":"C.B.","family":"Westphalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stenzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bayle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Bi\u00e8che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bonastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dienstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Czarnecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Michiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Normanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Reis-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Remon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Robson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2024.04.005_bib1","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib3","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.04.005_bib4","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA Approval Summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.04.005_bib5","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib6","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1158\/2159-8290.CD-19-1265","article-title":"Pan-cancer efficacy of vemurafenib in BRAF V600-mutant non-melanoma cancers","volume":"10","author":"Subbiah","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.04.005_bib8","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib9","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaoncol.2020.7684","article-title":"Response rates to anti-PD-1 immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase","volume":"7","author":"Valero","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib11","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1158\/2159-8290.CD-21-0450","article-title":"Atezolizumab treatment of tumors with high tumor mutational burden from mypathway, a multicenter, open-label, phase IIa multiple basket study","volume":"12","author":"Friedman","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.04.005_bib12","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.annonc.2024.04.005_bib13","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/JTO.0000000000000481","article-title":"Updated frequency of EGFR and KRAS mutations in nonsmall-cell lung cancer in Latin America: the Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)","volume":"10","author":"Arrieta","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2024.04.005_bib16","first-page":"S1254","article-title":"Amvantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer: primary results from MARIPOSA, a phase III, global, randomized, controlled trial","volume":"34","author":"Cho","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib19","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.annonc.2020.08.2100","article-title":"Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis","volume":"31","author":"Papadimitrakopoulou","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib20","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib21","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib22","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.19.00931","article-title":"Osimertinib for patients with non-small-cell lung cancer harboring uncommon egfr mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09)","volume":"38","author":"Cho","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib23","article-title":"Afatinib for the treatment of non-small cell lung cancer harboring uncommon EGFR mutations: an updated database of 1023 cases brief report","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib24","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib25","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib26","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-na\u00efve advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib27","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib28","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non\u2013small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib30","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2024.04.005_bib31","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-21-0800","article-title":"Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial","volume":"27","author":"Subbiah","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.04.005_bib32","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib34","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib35","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib36","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib37","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.annonc.2024.04.005_bib38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtho.2021.08.011","article-title":"Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis","volume":"17","author":"Planchard","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib39","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1200\/JCO.23.00774","article-title":"Phase II, open-label study of encorafenib plus binimetinib in patients with BRAFV600-mutant metastatic non-small-cell lung cancer","volume":"41","author":"Riely","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-019-0716-8","article-title":"Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration","volume":"26","author":"Drilon","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib41","doi-asserted-by":"crossref","first-page":"9020","DOI":"10.1200\/JCO.2021.39.15_suppl.9020","article-title":"Capmatinib in MET exon 14-mutated, advanced NSCLC: updated results from the GEOMETRY mono-1 study","volume":"39","author":"Wolf","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib42","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S2213-2600(21)00084-9","article-title":"Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study","volume":"9","author":"Lu","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib43","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jtho.2022.07.024","article-title":"OA03.05 Tepotinib in patients with MET Exon 14 (METex14) skipping NSCLC: primary analysis of the confirmatory VISION cohort C","volume":"17","author":"Thomas","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib44","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.annonc.2022.02.035","article-title":"26P Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung Cancer (aNSCLC): updated results from GEOMETRY mono-1","volume":"33","author":"Wolf","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib45","doi-asserted-by":"crossref","first-page":"S978","DOI":"10.1016\/j.annonc.2021.08.1844","article-title":"1239P ORCHARD osimertinib\u00a0+ savolitinib interim analysis: a biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib","volume":"32","author":"Yu","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib46","doi-asserted-by":"crossref","first-page":"9006","DOI":"10.1200\/JCO.2021.39.15_suppl.9006","article-title":"Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-na\u00efve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response","volume":"39","author":"Bauml","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib47","doi-asserted-by":"crossref","first-page":"9006","DOI":"10.1200\/JCO.2022.40.16_suppl.9006","article-title":"Amivantamab and lazertinib in patients with EGFR-mutant non\u2013small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: updated results from CHRYSALIS-2","volume":"40","author":"Shu","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib48","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.jtho.2022.07.114","article-title":"MA07.04 amivantamab and lazertinib in combination with platinum-based chemotherapy in relapsed\/refractory EGFR-mutant NSCLC","volume":"17","author":"Marmarelis","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib49","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib\u00a0+ savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.04.005_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.9021","article-title":"Tepotinib\u00a0+ osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib","volume":"41","author":"Tan","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2024.04.005_bib52","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non\u2013small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib53","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2022.40.16_suppl.105","article-title":"Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers","volume":"40","author":"Schram","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib54","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib55","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib56","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib57","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.20.00775","article-title":"Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial","volume":"38","author":"Lin","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib58","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib59","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jamaoncol.2020.7932","article-title":"Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial","volume":"7","author":"Rugo","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib60","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/2159-8290.CD-19-0966","article-title":"Efficacy and determinants of response to HER kinase inhibition in HER2-mutant metastatic breast cancer","volume":"10","author":"Smyth","year":"2020","journal-title":"Cancer Discov"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2024.04.005_bib61","first-page":"S458","article-title":"Efficacy and safety of trastuzumab deruxtecan (T-DXD) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): primary results from the international phase 2 DESTINY-PanTumor01 (DPT-01) study","volume":"34","author":"Li","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib62","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor\u2013positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib63","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(21)00034-6","article-title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","volume":"22","author":"Rugo","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib64","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib65","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-GS3-01","article-title":"Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+\/HER2- metastatic breast cancer: updated results by duration of prior CDK4\/6i in metastatic setting","volume":"83","author":"Bardia","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2024.04.005_bib66","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib67","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","article-title":"OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"184","author":"Robson","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2024.04.005_bib68","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib69","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.19.00368","article-title":"Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial","volume":"38","author":"Schmid","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib70","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor\u2013positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib71","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1001\/jamaoncol.2020.6741","article-title":"Effect of capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial","volume":"7","author":"Kalinsky","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib72","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s43018-022-00439-1","article-title":"A\u00a0phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes","volume":"3","author":"Gruber","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.annonc.2024.04.005_bib73","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib74","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.annonc.2022.01.006","article-title":"Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing","volume":"33","author":"Terraf","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib75","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.annonc.2021.08.2154","article-title":"Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD","volume":"32","author":"Hodgson","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib76","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib77","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"33","author":"Van Cutsem","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib78","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib79","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib80","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib81","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib82","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib83","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study","volume":"24","author":"Strickler","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib84","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/2159-8290.CD-21-0521","article-title":"PD-1 blockade in solid tumors with defects in polymerase epsilon","volume":"12","author":"Rousseau","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.04.005_bib85","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib86","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib87","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib88","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib89","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib90","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.annonc.2024.04.005_bib91","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss","volume":"25","author":"de Bono","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.04.005_bib92","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2024.04.005_bib93","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1200\/JCO.2022.40.16_suppl.5056","article-title":"Activation of the AKT pathway and outcomes in patients (pts) treated with or without ipatasertib (ipat) in metastatic castration-resistant prostate cancer (mCRPC): next-generation sequencing (NGS) data from the phase III IPATential150 trial","volume":"40","author":"Sweeney","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib94","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib95","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1158\/2159-8290.CD-21-0007","article-title":"Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial","volume":"11","author":"Carreira","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.04.005_bib96","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","article-title":"Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study","volume":"84","author":"Abida","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2024.04.005_bib97","author":"Gr\u00f6nberg"},{"key":"10.1016\/j.annonc.2024.04.005_bib99","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib100","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1200\/JCO.21.01604","article-title":"Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer","volume":"40","author":"Kindler","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib101","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C\u2013mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib102","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/JCO.2022.40.4_suppl.519","article-title":"KRYSTAL-1: updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation","volume":"40","author":"Bekaii-Saab","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib103","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib104","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2021.39.15_suppl.3003","article-title":"Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions","volume":"39","author":"Schram","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib105","article-title":"Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation","volume":"2018","author":"Shroff","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib106","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","article-title":"Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.annonc.2024.04.005_bib107","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1158\/1078-0432.CCR-22-3930","article-title":"Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer","volume":"29","author":"Singh","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.04.005_bib108","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/2159-8290.CD-21-1119","article-title":"Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements","volume":"12","author":"Schram","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.04.005_bib109","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2024.04.005_bib110","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib111","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2024.04.005_bib112","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib113","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib114","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib115","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib116","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib117","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib118","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.20.01164","article-title":"MILO\/ENGOT-ov11: binimetinib versus physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum","volume":"38","author":"Monk","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib119","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.379","article-title":"Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA","volume":"40","author":"Abou-Alfa","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib120","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib121","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","article-title":"Rare cancers are not so rare: the rare cancer burden in Europe","volume":"47","author":"Gatta","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2024.04.005_bib122","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","article-title":"Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study","volume":"18","author":"Gatta","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib123","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3322\/caac.21400","article-title":"The burden of rare cancers in the United States","volume":"67","author":"DeSantis","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2024.04.005_bib124","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib125","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib126","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib127","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.2023.41.4_suppl.610","article-title":"Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: expansion cohort results","volume":"41","author":"Pant","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib128","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib129","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib130","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3000","article-title":"Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results","volume":"41","author":"Meric-Bernstam","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib131","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib132","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib133","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.546","article-title":"Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2\/3 amplification (amp), overexpression (oe), or mutation (mut): results from the targeted agent and profiling utilization registry (TAPUR) study","volume":"41","author":"Cannon","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib134","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2024.04.005_bib135","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib136","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib137","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.annonc.2024.04.005_bib138","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib139","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2024.04.005_bib140","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2024.04.005_bib141","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib142","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib143","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.annonc.2024.04.005_bib144","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.21.00217","article-title":"Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: a randomized, open-label phase III Study","volume":"39","author":"Kang","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib145","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S2213-2600(18)30116-4","volume":"6","author":"Sch\u00f6ffski","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib146","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2021.07.016","article-title":"Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE","volume":"156","author":"Sch\u00f6ffski","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2024.04.005_bib147","first-page":"3719","article-title":"The dermatofibrosarcoma protuberans-associated collagen type I\u03b11\/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB1","volume":"59","author":"Shimizu","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2024.04.005_bib148","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1200\/JCO.2009.25.7899","article-title":"Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials","volume":"28","author":"Rutkowski","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib149","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1158\/0008-5472.CAN-04-3050","article-title":"SMARCB1\/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas","volume":"65","author":"Modena","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2024.04.005_bib150","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib151","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1200\/JCO.21.01728","article-title":"nab-Sirolimus for patients with malignant perivascular epithelioid cell tumors","volume":"39","author":"Wagner","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib152","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO\u2013EURACAN\u2013GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib153","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1038\/s41467-022-30496-0","article-title":"Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma","volume":"13","author":"Gounder","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2024.04.005_bib154","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"key":"10.1016\/j.annonc.2024.04.005_bib155","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib156","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1158\/1078-0432.CCR-21-0967","article-title":"FDA approval summary: pralsetinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.04.005_bib157","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1200\/JCO.2022.40.16_suppl.6080","article-title":"Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC): updated data from the ARROW trial","volume":"40","author":"Mansfield","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib158","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.04.005_bib159","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Agrawal","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2024.04.005_bib160","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib161","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib162","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","article-title":"ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer","volume":"33","author":"Filetti","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib163","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-20-3558","article-title":"FDA Approval summary: selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions","volume":"27","author":"Bradford","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.04.005_bib164","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1002\/onco.13597","article-title":"Comprehensive genomic profiling of carcinoma of unknown primary origin: retrospective molecular classification considering the CUPISCO study design","volume":"26","author":"Ross","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2024.04.005_bib165","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.annonc.2021.11.009","article-title":"Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary","volume":"33","author":"Tanizaki","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib166","doi-asserted-by":"crossref","first-page":"S881","DOI":"10.1016\/j.annonc.2022.07.864","article-title":"738P Combined ipilimumab and nivolumab in previously treated patients with cancer of unknown primary: results of the CheCUP trial","volume":"33","author":"Pouyiourou","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib167","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.1038\/s41467-023-42400-5","article-title":"Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial","volume":"14","author":"Pouyiourou","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2024.04.005_bib168","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2014.216","article-title":"Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies","volume":"1","author":"Ross","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib169","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1002\/ijc.32882","article-title":"Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary","volume":"146","author":"Bochtler","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.annonc.2024.04.005_bib170","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1038\/s41467-022-31866-4","article-title":"Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity","volume":"13","author":"M\u00f6hrmann","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2024.04.005_bib171","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2023.10.006","volume":"34","author":"Mileshkin","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib172","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","article-title":"Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Kr\u00e4mer","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib173","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/gcc.23022","article-title":"Fusion-positive non-small cell lung carcinoma: biological principles, clinical practice, and diagnostic implications","volume":"61","author":"Kazdal","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.annonc.2024.04.005_bib174","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","article-title":"Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing","volume":"127","author":"Neumann","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2024.04.005_bib175","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","article-title":"High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden","volume":"25","author":"Benayed","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.04.005_bib176","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.3390\/ijms21186856","article-title":"FGFR fusions in cancer: from diagnostic approaches to therapeutic intervention","volume":"21","author":"De Luca","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.annonc.2024.04.005_bib177","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.04.005_bib178","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2024.04.005_bib179","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.annonc.2022.12.003","article-title":"Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations","volume":"34","author":"Kuzbari","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib180","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.annonc.2021.09.002","article-title":"Detection of additional occult malignancy through profiling of ctDNA in late-stage cancer patients","volume":"32","author":"Aldea","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib181","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2024.04.005_bib182","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1158\/0008-5472.CAN-22-0985","article-title":"Clonal hematopoiesis of indeterminate potential in patients with solid tumor malignancies","volume":"82","author":"Marshall","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2024.04.005_bib183","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.annonc.2024.04.005_bib184","article-title":"Liquid biopsies for circulating tumor DNA detection may reveal occult hematologic malignancies in patients with solid tumors","volume":"7","author":"Aldea","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib185","article-title":"Cost-effectiveness of next-generation sequencing versus single-gene testing for the molecular diagnosis of patients with metastatic non\u2013small-cell lung cancer from the perspective of Spanish reference centers","volume":"7","author":"Arriola","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib186","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/14737167.2022.2078310","article-title":"Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective","volume":"22","author":"de Alava","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.annonc.2024.04.005_bib187","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2019.11.022","article-title":"Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: incremental yield of actionable alterations and cost-effectiveness analysis","volume":"139","author":"Tan","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annonc.2024.04.005_bib188","article-title":"Cost-effectiveness of parallel versus sequential testing of genetic aberrations for stage IV non-small-cell lung cancer in the Netherlands","volume":"6","author":"Wolff","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib189","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jmoldx.2022.04.010","article-title":"Diagnostic value and cost-effectiveness of next-generation sequencing-based testing for treatment of patients with advanced\/metastatic non-squamous non-small-cell lung cancer in the United States","volume":"24","author":"Zou","year":"2022","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.annonc.2024.04.005_bib190","article-title":"Modeling costs and life-years gained by population-wide next-generation sequencing or single-gene testing in nonsquamous non-small-cell lung cancer in the United States","volume":"7","author":"Lemmon","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib191","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2217\/fon-2021-1040","article-title":"Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review","volume":"18","author":"Zheng","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib192","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.annonc.2023.06.011","article-title":"ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib193","article-title":"Molecular-guided off-label targeted therapy in a large-scale precision oncology program","volume":"7","author":"Vashistha","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2024.04.005_bib194","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","article-title":"Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial","volume":"17","author":"Brose","year":"2016","journal-title":"Lancet Oncol"}],"updated-by":[{"DOI":"10.1016\/j.annonc.2024.11.010","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000}}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342400111X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342400111X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T12:30:49Z","timestamp":1739277049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342400111X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":193,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S092375342400111X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2024.04.005","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2024.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}